![]() A single compound can take as many as 20 years to become an approved drug and cost 2–3 billion of dollars in research and development. The process of translating a compound of therapeutic potential from the benchtop to the drug market is a rigorous one involving many hurdles in terms of time, money, and human resources. This review profiles the deep insights that X-ray structural techniques and associated analytical methods can offer in the development of a drug. Natural or biomimetic products are often used as the API or the formulation agent. This information is vital for appropriate formulation of a drug for stability, administration, and efficacy purposes. ASDs are made up of an active pharmaceutical ingredient (API) within a drug dispersed at the molecular level in an amorphous polymeric carrier. PDF has been used in the study of amorphous solid dispersions (ASDs). One valuable technique employed to determine atomic arrangements and local atom ordering of amorphous materials is the pair distribution function (PDF). ![]() Recently, synchrotron sources have enabled wider access to the study of noncrystalline or amorphous solids. ![]() Powder X-ray diffraction (PXRD) has provided a method to determine the different phases, purity, and stability of biological drug compounds that possess crystallinity. Single crystal X-ray diffraction (SCXRD) reveals important structural details and molecular interactions for the manifestation of a disease or for therapeutic effect. ![]() X-ray structural characterization approaches have catalyzed the drug discovery and design process. To decrease the time to drug approval, efforts are focused on drug targets and drug formulation for optimal biocompatibility and efficacy. Drug development is a decades-long, multibillion dollar investment that often limits itself. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |